GlassScriptPhysician profile
Debra S Kime
NPI 1114982709
$5,500.47
in general payments reported to CMS, 2019-2025
35 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,278 · 2022: $910 · 2023: $704 · 2024: $1,017 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,302 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,301.69 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,610.92 | 2021-2025 | |
| Janssen Biotech, INC. | $689.63 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $606.66 | 2021-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $439.79 | 2021-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $390.80 | 2021-2025 | Livdelzi, Epclusa |
| Pfizer INC. | $209.58 | 2021-2023 | |
| Medtronic, INC. | $189.30 | 2023-2025 | Interstim |
| Intercept Pharmaceuticals, INC. | $170.66 | 2021-2024 | Ocaliva |
| Celgene Corporation | $166.12 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $165.17 | 2021-2023 | Dificid |
| Ardelyx, INC. | $141.86 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $125.27 | 2022-2025 | Dupixent |
| Evoke Pharma, INC. | $77.94 | 2021-2025 | Gimoti |
| Organon LLC | $56.04 | 2023-2024 | Renflexis |
| Daiichi Sankyo INC. | $45.67 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $37.42 | 2022-2023 | |
| Lilly USA, LLC | $34.30 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $32.23 | 2024-2025 | Voquezna |
| Amgen INC. | $29.86 | 2021 | |
| Braintree Laboratories, INC. | $26.02 | 2021 | |
| Genzyme Corporation | $24.92 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $21.47 | 2025 | Iqirvo |
| Vivus LLC | $20.59 | 2021 | |
| Ironwood Pharmaceuticals, INC | $20.40 | 2022 | |
| Fresenius Kabi USA, LLC | $19.32 | 2023 | |
| Madrigal Pharmaceuticals | $18.33 | 2025 | Rezdiffra |
| Mauna Kea Technologies, INC. | $17.37 | 2025 | |
| Ethicon US, LLC | $16.69 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.20 | 2024 | Rebyota |
| Boston Scientific Corporation | $16.02 | 2021 | |
| Aimmune Therapeutics, INC. | $15.80 | 2025 | Zenpep |
| Exact Sciences Corporation | $13.88 | 2023 | Cologuard Collection Kit |
| Csl Behring | $12.76 | 2021 | |
| Intra-Sana Laboratories | $11.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Kime listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.